Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free ACHL Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Achilles Therapeutics (ACHL) Competitors

Achilles Therapeutics logo
Compare

ACHL vs. ARCT, NVCT, HRTX, TENX, and KROS

Should you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Arcturus Therapeutics (ARCT), Nuvectis Pharma (NVCT), Heron Therapeutics (HRTX), Tenax Therapeutics (TENX), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical products" industry.

How does Achilles Therapeutics compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Arcturus Therapeutics has higher revenue and earnings than Achilles Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$82.03M3.08-$65.78M-$2.38N/A
Achilles TherapeuticsN/AN/A-$69.67M-$1.65N/A

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arcturus Therapeutics currently has a consensus target price of $29.50, indicating a potential upside of 231.46%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Arcturus Therapeutics is more favorable than Achilles Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69
Achilles Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Achilles Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -80.19%. Arcturus Therapeutics' return on equity of -29.13% beat Achilles Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcturus Therapeutics-80.19% -29.13% -22.03%
Achilles Therapeutics N/A -54.45%-47.68%

In the previous week, Arcturus Therapeutics had 6 more articles in the media than Achilles Therapeutics. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 0 mentions for Achilles Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.20 beat Achilles Therapeutics' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Arcturus Therapeutics Neutral
Achilles Therapeutics Neutral

Arcturus Therapeutics has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.

Summary

Arcturus Therapeutics beats Achilles Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Achilles Therapeutics compare to Nuvectis Pharma?

Achilles Therapeutics (NASDAQ:ACHL) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

In the previous week, Nuvectis Pharma had 11 more articles in the media than Achilles Therapeutics. MarketBeat recorded 11 mentions for Nuvectis Pharma and 0 mentions for Achilles Therapeutics. Nuvectis Pharma's average media sentiment score of 0.89 beat Achilles Therapeutics' score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Achilles Therapeutics Neutral
Nuvectis Pharma Positive

Nuvectis Pharma has a consensus target price of $10.00, suggesting a potential downside of 3.10%. Given Nuvectis Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Nuvectis Pharma is more favorable than Achilles Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Achilles Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Nuvectis Pharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by company insiders. Comparatively, 30.5% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Achilles TherapeuticsN/AN/A-$69.67M-$1.65N/A
Nuvectis PharmaN/AN/A-$26.44M-$1.31N/A

Achilles Therapeutics' return on equity of -54.45% beat Nuvectis Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Achilles TherapeuticsN/A -54.45% -47.68%
Nuvectis Pharma N/A -161.00%-98.88%

Achilles Therapeutics has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500.

Summary

Nuvectis Pharma beats Achilles Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Achilles Therapeutics compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Achilles Therapeutics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -13.04%. Heron Therapeutics' return on equity of 0.00% beat Achilles Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Heron Therapeutics-13.04% N/A -4.62%
Achilles Therapeutics N/A -54.45%-47.68%

In the previous week, Achilles Therapeutics' average media sentiment score of 0.00 beat Heron Therapeutics' score of -1.00 indicating that Achilles Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Heron Therapeutics Negative
Achilles Therapeutics Neutral

Heron Therapeutics currently has a consensus target price of $4.50, suggesting a potential upside of 262.90%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Achilles Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heron Therapeutics
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
Achilles Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Heron Therapeutics has higher revenue and earnings than Achilles Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$154.90M1.51-$20.19M-$0.13N/A
Achilles TherapeuticsN/AN/A-$69.67M-$1.65N/A

80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are held by institutional investors. 5.9% of Heron Therapeutics shares are held by insiders. Comparatively, 5.4% of Achilles Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Heron Therapeutics has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.

Summary

Heron Therapeutics beats Achilles Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Achilles Therapeutics compare to Tenax Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are held by institutional investors. 3.1% of Tenax Therapeutics shares are held by insiders. Comparatively, 5.4% of Achilles Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Tenax Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Achilles Therapeutics has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenax TherapeuticsN/AN/A-$52.60M-$1.33N/A
Achilles TherapeuticsN/AN/A-$69.67M-$1.65N/A

Tenax Therapeutics currently has a consensus target price of $29.67, indicating a potential upside of 154.65%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Tenax Therapeutics is more favorable than Achilles Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenax Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83
Achilles Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Tenax Therapeutics' return on equity of -51.83% beat Achilles Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tenax TherapeuticsN/A -51.83% -49.51%
Achilles Therapeutics N/A -54.45%-47.68%

In the previous week, Tenax Therapeutics had 4 more articles in the media than Achilles Therapeutics. MarketBeat recorded 4 mentions for Tenax Therapeutics and 0 mentions for Achilles Therapeutics. Tenax Therapeutics' average media sentiment score of 0.34 beat Achilles Therapeutics' score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Tenax Therapeutics Neutral
Achilles Therapeutics Neutral

Summary

Tenax Therapeutics beats Achilles Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Achilles Therapeutics compare to Keros Therapeutics?

Achilles Therapeutics (NASDAQ:ACHL) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Achilles Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by company insiders. Comparatively, 20.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Keros Therapeutics has a consensus target price of $21.33, indicating a potential upside of 83.28%. Given Keros Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Keros Therapeutics is more favorable than Achilles Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Achilles Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Keros Therapeutics
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Keros Therapeutics had 2 more articles in the media than Achilles Therapeutics. MarketBeat recorded 2 mentions for Keros Therapeutics and 0 mentions for Achilles Therapeutics. Keros Therapeutics' average media sentiment score of 0.78 beat Achilles Therapeutics' score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Achilles Therapeutics Neutral
Keros Therapeutics Positive

Keros Therapeutics has a net margin of 35.65% compared to Achilles Therapeutics' net margin of 0.00%. Keros Therapeutics' return on equity of 14.25% beat Achilles Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Achilles TherapeuticsN/A -54.45% -47.68%
Keros Therapeutics 35.65%14.25%13.27%

Keros Therapeutics has higher revenue and earnings than Achilles Therapeutics. Achilles Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Achilles TherapeuticsN/AN/A-$69.67M-$1.65N/A
Keros Therapeutics$244.06M0.94$87.01M$1.826.40

Summary

Keros Therapeutics beats Achilles Therapeutics on 14 of the 15 factors compared between the two stocks.

Get Achilles Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACHL vs. The Competition

Export
MetricAchilles TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$60.83M$328.26M$6.31B$12.15B
Dividend YieldN/AN/A2.77%5.24%
P/E Ratio-0.90N/A28.6827.01
Price / SalesN/A178.96528.9177.57
Price / CashN/A22.4443.3053.97
Price / Book0.424.739.866.89
Net Income-$69.67M-$132.96M$3.55B$333.11M

Achilles Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACHL
Achilles Therapeutics
N/A$1.48
flat		N/AN/A$60.83MN/AN/A250
ARCT
Arcturus Therapeutics
2.0993 of 5 stars		$8.40
-5.3%		$29.50
+251.2%		-18.7%$238.73M$82.03MN/A180
NVCT
Nuvectis Pharma
0.8412 of 5 stars		$8.50
-2.2%		$10.00
+17.6%		+17.5%$225.17MN/AN/A8
HRTX
Heron Therapeutics
1.572 of 5 stars		$1.19
-1.7%		$4.50
+278.2%		-45.0%$224.48M$154.90MN/A300
TENX
Tenax Therapeutics
2.063 of 5 stars		$12.78
-12.5%		$29.67
+132.1%		+109.2%$219.82MN/AN/A9

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ACHL) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever
"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...
Chaikin Analytics | Sponsoredtc pixel
Why I flew on a tiny helicopter next to a potential nuclear bomb target
Satellite Confirms: Elon Musk Activating Strange 'Dark Energy' Across U.S. South Confirmed by satellites 30...
Altimetry | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel
Is the SpaceX IPO “Rigged?”
The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...
The Oxford Club | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel